Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy

• Published in: The journal of clinical endocrinology and metabolism 2019-03, Vol.104 (3), p.779-784
• Main Authors: Colombo, Carla, De Leo, Simone, Di Stefano, Marta, Vannucchi, Guia, Persani, Luca, Fugazzola, Laura
• Format: Article
• Language: English
• Subjects: Acetates; Acetic acid; ACTH; Addison Disease - chemically induced; Addison Disease - complications; Addison Disease - drug therapy; Adrenal glands; Adrenocorticotropic hormone; Adult; Aged; Carcinoma, Neuroendocrine - drug therapy; Case Report; Child; Cortisone; Cortisone - therapeutic use; Dose-Response Relationship, Drug; Fatigue; Fatigue - drug therapy; Fatigue - etiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient satisfaction; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - adverse effects; Piperidines - administration & dosage; Piperidines - adverse effects; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein-tyrosine kinase; Quinazolines - administration & dosage; Quinazolines - adverse effects; Quinolines - administration & dosage; Quinolines - adverse effects; Terminology; Thyroid cancer; Thyroid Neoplasms - drug therapy; Treatment Outcome; Tyrosine; Vandetanib; Young Adult
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2018-01836

Two tyrosine kinase inhibitors (TKIs), lenvatinib and vandetanib, are often used to treat advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) and medullary thyroid cancer (MTC), respectively. Fatigue is a common adverse event during treatment with these and other TKIs and a common cause of drug discontinuation or dosage reduction. We evaluated the basal and stimulated adrenal function in 12 patients with advanced RAI-R DTC and MTC treated with lenvatinib or vandetanib, respectively. Ten patients complaining of fatigue showed a progressive ACTH increase with normal cortisol levels. Moreover, six of 10 patients had a blunted cortisol response after ACTH stimulation, thus confirming the diagnosis of primary adrenal insufficiency (PAI). The causal relationship between TKIs and PAI onset was also demonstrated by the repeated testing of adrenal function before and during treatment. Patients with PAI received cortisone acetate replacement therapy, with a substantial and prompt improvement in the degree of fatigue, as assessed by the Common Terminology Criteria for Adverse Events version 4.03, thus supporting the major impact of impaired adrenal function in the genesis of this adverse event. We show that the occurrence of PAI may be a common cause of fatigue during lenvatinib and vandetanib treatment, and we therefore recommend testing adrenal function for a prompt start of replacement therapy to avoid treatment discontinuation, dosage reduction, and potentially severe PAI complications.